Chemo Research, 28050 Madrid, Spain.
Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23407, USA.
Int J Mol Sci. 2024 Jul 12;25(14):7667. doi: 10.3390/ijms25147667.
With the aim to shorten the time for diagnosis and accelerate access to correct management, a non-invasive diagnostic test for endometriosis was developed and validated. The IVD test combines an ELISA test kit to quantify CA125 and BDNF concentrations in serum and a data treatment algorithm hosted in medical software processing results from the ELISA test and responses to six clinical variables. Serum samples and clinical variables extracted from psychometric questionnaires from 77 patients were collected from the Oxford Endometriosis CaRe Centre biobank (UK). Case/control classification was performed based on laparoscopy and histological verification of the excised lesions. Biomarkers serum concentrations and clinical variables were introduced to the software, which generates the qualitative diagnostic result ("positive" or "negative"). This test allowed the detection of 32% of cases with superficial endometriosis, which is an added value given the limited efficacy of existing imaging techniques. Even in the presence of various confounding medical conditions, the test maintained a specificity of 100%, supporting its suitability for use in patients with underlying medical conditions.
为了缩短诊断时间并加速获得正确的管理,开发并验证了一种用于子宫内膜异位症的非侵入性诊断测试。该体外诊断测试结合了 ELISA 试剂盒,用于定量血清中 CA125 和 BDNF 的浓度,以及托管在医学软件中的数据处理算法,用于处理 ELISA 测试的结果和对六个临床变量的响应。从英国牛津子宫内膜异位症 CaRe 中心生物银行收集了来自 77 名患者的血清样本和心理计量学问卷中的临床变量。基于腹腔镜检查和切除病变的组织学验证进行病例/对照分类。将生物标志物血清浓度和临床变量引入软件,该软件生成定性诊断结果(“阳性”或“阴性”)。该测试可检测到 32%的浅层子宫内膜异位症病例,鉴于现有成像技术的疗效有限,这是一个附加值。即使存在各种混杂的医疗条件,该测试仍保持 100%的特异性,支持其在患有基础疾病的患者中使用的适用性。